To provide direct evidence and assess the relative roles of these cells, we herein used antibodies to CD4 and CD8 molecules to deplete CD4+ or CD8+ T cells one day before vaccination with the optimized therapeutic SA-4-1BBL/E7 formulation using the TC-1 tumor model (Fig. 4A). The gene discussed is CD8A; the disease is neoplasm.